Ballicules.com

Rasagiline

AZILECT

What it isIrreversible MAO-B inhibitor; Parkinson disease.

Why this oneOnce daily with no amphetamine metabolites, unlike selegiline.

What limits itSelectivity is lost at higher doses, so tyramine and serotonergic precautions apply. Modest symptomatic effect.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Parkinson's disease — monotherapy or adjunct without levodopaAdults1 mg QD1 mg QD1 mg/day
Parkinson's disease — adjunct to levodopaAdults0.5 mg QD1 mg QD if needed1 mg/day
With ciprofloxacin/other CYP1A2 inhibitorsAdults0.5 mg QD0.5 mg QD0.5 mg/day

Renal No adjustment for mild-moderate impairment; not studied in severe

Hepatic Mild impairment: do not exceed 0.5 mg QD; not for use in moderate or severe impairment

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy No adequate human data; decreased offspring survival/weight in animals

Lactation No human data; may inhibit prolactin secretion

NO BOXED WARNINGS

Principal riskSelectivity lost at higher doses; tyramine precautions

Cost, est. cash$10–$500/month

Generic entry2013

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability1 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryC

Defining liabilityOrthostasis, hallucinations, dyskinesia and impulse-control symptoms; abrupt withdrawal can be hazardous.

Mechanism of action: Rasagiline ballicule

Rasagiline ballicule: receptor binding, kinetics and half-life diagram

Open Rasagiline in the interactive console ↗

Memory aids: mascots and interaction avatars

Rasagiline AZILECT mascot mnemonic cartoon
“Raise a lean Aztec”
Mao Zedong → MAOI
Rasagiline CYP1A2 substrate avatar
CYP1A2 substrate

Open Rasagiline in the interactive console ↗